Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Datadog Inc (DDOG) vs Johnson & Johnson (JNJ) Price & Performance

Datadog IncTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Datadog Inc vs Johnson & Johnson — how do they compare? Datadog Inc trades at $240.59 (market cap $88.61B), while Johnson & Johnson trades at $260.91 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 7.1× Datadog Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.

DDOGJNJ
Market Cap
$88.61B$626.09B
Sector
TechnologyHealth
52-Week High
$288.15$267.24
52-Week Low
$102.62$172.78
Enterprise Value
$84.90B$654.37B
Volume
6,156,228
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Datadog Inc

Datadog (DDOG) trades at $244.2, down 6.36% over 24 hours, with a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. Revenue grew 36% year-over-year to $1.12 billion, but the stock faces pressure from high valuations (P/E 493.56) and concerns over a major customer's reduced usage. Analyst consensus remains strongly bullish with an 83.34% buy rating and a $288.55 price target, suggesting significant upside potential from current levels.

The outlook is mixed: robust fundamentals and AI-driven growth support long-term value, but near-term volatility persists due to premium valuation and investor skepticism post-earnings. Key risks include customer concentration, competitive pressures, and execution challenges in sustaining high growth rates. Investors should weigh strong analyst conviction against technical weakness and market sentiment shifts.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ